WP
CGON icon

Woodline Partners’s CG Oncology CGON Stock Holding History

Woodline Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35M Hold
492,891
– – 0.11% 248
2026
Q1 		$33.4M Buy
492,891
+391
+0.1% +$22.2K 0.13% 215
2025
Q4 		$20.4M Sell
492,500
-78,978
-14% -$3.27M 0.08% 307
2025
Q3 		$23M Sell
571,478
-57,879
-9% -$1.68M 0.11% 252
2025
Q2 		$16.4M Sell
629,357
-135,000
-18% -$3.25M 0.09% 326
2025
Q1 		$18.7M Buy
764,357
+135,472
+22% +$3.81M 0.12% 240
2024
Q4 		$18M Buy
628,885
+22,987
+4% +$786K 0.12% 229
2024
Q3 		$22.9M Buy
605,898
+80,699
+15% +$2.83M 0.19% 174
2024
Q2 		$16.6M Hold
525,199
– – 0.16% 193
2024
Q1 		$23.1M Buy
+525,199
New +$21.4M 0.21% 147

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's CGON Position: Q2 2026 in Review

Woodline Partners held its CG Oncology (CGON) position steady in Q2 2026 at 492,891 shares worth $35M. The position accounts for 0.11% of the portfolio, ranked #248.

Woodline Partners first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Woodline Partners held 492,891 shares of CG Oncology worth $35M as of Q2 2026.
  • Woodline Partners left its CG Oncology share count unchanged in Q2 2026.
  • CG Oncology made up 0.11% of Woodline Partners's portfolio in Q2 2026, its #248 holding.
  • Woodline Partners first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.